ArticleEuropean clinical respiratory journal2020
Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis.
Article in European clinical respiratory journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Economic burden and cost drivers of interstitial lung disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Comparison of the health-related outcomes for traditional cigarettes, e-cigarettes, heat-not-burn cigarettes and snus: a systematic review and meta-analysis.BMC public health · 2026Pooled it
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.BMC pulmonary medicine · 2021Pooled it
- Potential association of bronchoalveolar lavage lipid-laden macrophages with disease severity and corticosteroid response in interstitial lung disease: a pilot study.Journal of thoracic disease · 2026Article
- FRED scoring system for interstitial lung disease: Predicting exacerbations requiring admissions need for long-term oxygen therapy and mortality.Lung India : official organ of Indian Chest Society · 2026Article
- Distinct comorbidity profiles and outcomes in asbestosis versus idiopathic pulmonary fibrosis: a 6-year prospective cohort study.BMC pulmonary medicine · 2026Article
- Oxygen desaturation and lung ultrasonography as markers of diffuse parenchymal lung diseases severity.PloS one · 2025Article
- Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections-a systematic review and a meta-analysis.EClinicalMedicine · 2025Article
- Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry.Respiratory research · 2024Article
- Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study).PharmacoEconomics · 2023Observational
- Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.Medicina (Kaunas, Lithuania) · 2023Article
- Historical eye on IPF: a cohort study redefining the mortality scenario.Frontiers in medicine · 2023Article
- Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry.Pulmonary therapy · 2022Article
- Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.Arthritis research & therapy · 2022Article
- Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.ERJ open research · 2022Review
- Article
- Clinical significance of pectoralis muscle strength in elderly patients with idiopathic pulmonary fibrosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Article
- Clinical implications of frailty assessed in hospitalized patients with acute-exacerbation of interstitial lung disease.Chronic respiratory diseaseArticle
- Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.